WSC 2022 | Could tenecteplase replace alteplase as a treatment for acute ischemic stroke?

Nishita Singh, MD, University of Calgary, Calgary, Alberta, Canada, discusses intravenous tenecteplase compared with alteplase for acute ischemic stroke. Owing to the COVID-19 pandemic and resultant supply chain issues, there was a change in practice ahead of change in guidelines, with many centers shifting to tenecteplase use due to practical and logistical reasons. The recently published AcT study (NCT03889249) is the first large-scale Phase III trial which has proven tenecteplase to be non-inferior to alteplase, suggesting tenecteplase use could be a reasonable alternative in the future. There is a need for appropriate use guidelines now that supporting evidence has been collected. This interview took place at the World Stroke Congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.